In a report released yesterday, Charles Duncan from Cantor Fitzgerald initiated coverage with a Buy rating on Alkermes (ALKS – Research ...

Trump's campaign is reportedly holding up the presidential transition process to ice out affiliates of Project 2025 ...

Cantor Fitzgerald lowered the firm’s price target on Alkermes (ALKS) to $43 from $48 and keeps an Overweight rating on the shares.

It's a significant leap into politics for the Cantor Fitzgerald CEO, who has given $65 million to Haverford over several ...

Eric Johnston, Cantor Fitzgerald chief equity and macro strategist, joins 'Closing Bell' to discuss the bullish case for ...

Cantor Fitzgerald reissued their overweight rating on shares of Zura Bio (NASDAQ:ZURA – Free Report) in a report published on ...

Cantor Fitzgerald lowered shares of Lilium (NASDAQ:LILM – Free Report) from an overweight rating to a neutral rating in a research report released on Friday, Ratings reports. Cantor Fitzgerald ...

Cantor Fitzgerald has recently reduced Anavex Life Sciences Corp (AVXL) stock to Neutral rating, as announced on December 6, 2022, according to Finviz. Earlier, on June 23, 2022, Berenberg had ...

InvestingPro的数据进一步阐明了Impinj的近期表现和未来前景。该公司股票表现出色，过去一年的价格总回报率为319.18%，过去六个月的回报率为83.99%。这与Cantor Fitzgerald上调价格目标所表达的积极情绪相一致。

Eric Johnston，Cantor Fitzgerald的首席策略师，表示小盘股在大选前后通常表现优异。历史数据显示，在过去11个大选年中，有4年的罗素2000指数在大选前后上涨超过6.5%。更重要的是，预计在年底之前，这一指数的涨幅可能会超过12%。这种季节性的波动性为投资者提供了不错的短期交易机会。在这一背景下，投资者应该密切关注罗素2000指数的走势，以获取潜在的超额回报。

周三，Cantor Fitzgerald重申了对CVRx Inc (NASDAQ:CVRX)的信心，维持其超配评级和14.00美元的目标价。该公司的认可是在对心力衰竭专家、心脏病专家和心电生理学家进行调查之后做出的，旨在评估医学界对CVRx的Barostim技术的认知和采用情况。 这项包含30位医生回应的调查旨在了解影响心力衰竭治疗领域的各种因素。结果显示，对CVRx的Barostim产品的认可度 ...

智通财经APP获悉，美国金融服务公司Cantor Fitzgerald表示看好罗素2000指数，因为其认为共和党总统候选人特朗普赢得11月美国总统大选的可能性高于市场预期，特朗普重返白宫将有利于小盘股。 周二公布的一项民意调查显示，民主党总统候选人哈里斯与特朗普的竞争愈发激烈，两名候选人在选民中的支持率都是48%。而上个月的民意调查显示，哈里斯以49%对44%的支持率领先特朗普5个百分点。